Source: Zhitong Finance
$Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK) $According to the announcement, the closing price increase of the company's A-share shares deviated by more than 20% for two consecutive trading days on May 6 and May 9, 2022. The company disclosed the “Notice Concerning Abnormal Fluctuations in A-Share Trading” on May 10, 2022. On May 10 and May 11, 2022, the company's A-shares continued to rise and stop.
The company's current production and operation situation is normal. There have been no major changes in its main business, external market environment, or industry policies, and there is no other significant information that should have been disclosed but not disclosed.
As for the risks and uncertainties relating to the implementation of the Strategic Cooperation Agreement. This agreement is a strategic cooperation agreement signed between the company and Henan Real Biotechnology Co., Ltd. (“Real Life”). It is based on the needs of the company's strategic development and judgment on the market prospects of the industry. There are certain market risks, and there is uncertainty about the future operating benefits of the cooperative project.
What needs special reminder is that Azivudine held by Real Life is an anti-AIDS drug that was approved by the National Drug Administration in 2021. Currently, new clinical trials are an indication against the novel coronavirus. Clinical trial results for real-life biotherapy for this indication have not been publicly released, and this indication has not been approved by the National Drug Administration.
The company will fulfill its information disclosure obligations in accordance with relevant regulations such as the “Shenzhen Stock Exchange Stock Listing Rules” and the “Articles of Association” in accordance with the progress of cooperation matters.